Financial

  • Aug. 29, 2019 Bioasis Announces Stock Option Grants

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced… Read more »

  • Jul. 26, 2019 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2019

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »

  • Jul. 17, 2019 Bioasis Announces Stock Option Grants

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced… Read more »

  • May. 21, 2019 Bioasis Announces Closing of Previously Disclosed Private Placement

    THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

  • May. 6, 2019 Bioasis Announces Private Placement

    This News Release is Not for Distribution to U.S. Newswire Services or Dissemination in the United States

  • Mar. 25, 2019 Bioasis Technologies Inc. Announces Warrant Extension

    GUILFORD, Conn. — (BUSINESS WIRE) — BIOASIS TECHNOLOGIES INC. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative… Read more »

  • Jan. 29, 2019 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited… Read more »

  • Nov. 26, 2018 Bioasis Announces Voting Results for 2018 Annual and Special Meeting

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the voting results from its Annual & Special… Read more »

  • Oct. 30, 2018 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited… Read more »

  • Oct. 29, 2018 Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena

    Under the terms of the agreement, Bioasis to receive a US$1 million upfront payment from Prothena, plus additional potential option exercise, regulatory and commercial milestone payments, plus additional royalties on net sales from licensed products Prothena will receive a worldwide, exclusive license to use the xB 3  platform with an undisclosed neurodegenerative disease target as well as the option for three additional neuroscience targets